Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Clin Calcium ; 25(9): 1367-72, 2015 Sep.
Article in Japanese | MEDLINE | ID: mdl-26320537

ABSTRACT

Glucocorticoid and sex-steroid deprivation therapies are two major causes of medication-related osteoporosis. As clinical course of osteoporosis is rather chronic, other drugs for common chronic diseases could also affect the incidence of osteoporotic fracture. Peroxisome proliferator-activated receptor-γ agonist, loop diuretics, selective serotonin reuptake inhibitor, anticonvulsants and proton pump inhibitors are now considered to be important candidates as the cause of medication-related osteoporosis.


Subject(s)
Osteoporosis/chemically induced , Aging , Bone Density , Humans , Osteoporotic Fractures/chemically induced , Practice Guidelines as Topic , Risk Factors
2.
Clin Calcium ; 25(4): 559-63, 2015 Apr.
Article in Japanese | MEDLINE | ID: mdl-25814017

ABSTRACT

Osteoporosis liaison service (OLS) is a coordinator-based service provided by Japan Osteoporosis Society. Fracture Liaison Services, commonly known as FLS, are coordinator-based, secondary fracture prevention services implemented by health care systems for the treatment of osteoporotic patients. OLS includes not only FLS but also educational program, medical check-up for bone fragility and risk assessment for primary fracture in osteoporotic subjects. Japan Osteoporosis Society gives coordinators the certificate as a specialist for OLS since 2015. OLS in Japan should facilitate better performance of the treatment of osteoporosis and should contribute the reduction of clinical fractures.


Subject(s)
Delivery of Health Care , Hip Fractures/therapy , Osteoporosis/therapy , Osteoporotic Fractures/therapy , Secondary Prevention , Hip Fractures/prevention & control , Humans , Japan , Osteoporosis/prevention & control , Osteoporotic Fractures/prevention & control , Risk Assessment
3.
J Diabetes Complications ; 33(11): 107415, 2019 11.
Article in English | MEDLINE | ID: mdl-31466840

ABSTRACT

AIMS: The aim of this study is to investigate the effects of a low-carbohydrate staple food (i.e., low-carbohydrate bread) on glucose and lipid metabolism and pancreatic and enteroendocrine hormone secretion in comparison with meals containing normal-carbohydrate bread, without consideration of the carbohydrate content of the side dishes. METHODS: T2DM patients (n = 41) were provided meals containing low-carbohydrate bread (LB) together with side dishes or normal-carbohydrate bread (NB) together with side dishes every other day as a breakfast. Blood glucose levels were evaluated by using a continuous glucose monitoring system; blood samples were collected before and 1 and 2 h after the breakfast. RESULTS: Postprandial blood glucose levels, plasma insulin, plasma glucose-dependent insulinotropic polypeptide (GIP) and plasma triglyceride were significantly lower and plasma glucagon levels were significantly higher in LB compared with those in NB. Plasma glucagon-like peptide-1 (GLP-1) levels did not differ in the LB and NB groups. CONCLUSIONS: These results indicate that changing only the carbohydrate content of the staple food has benefits on glucose and lipid metabolism in T2DM patients concomitant with the decrease of insulin and GIP secretion, which ameliorate body weight gain and insulin resistance.


Subject(s)
C-Peptide/blood , Diabetes Mellitus, Type 2/diet therapy , Diet, Carbohydrate-Restricted/methods , Gastric Inhibitory Polypeptide/blood , Postprandial Period/physiology , Adult , Aged , Blood Glucose/metabolism , Blood Glucose Self-Monitoring , Bread , Breakfast , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Feeding Behavior , Female , Glycemic Load , Humans , Hypoglycemic Agents/therapeutic use , Lipid Metabolism , Lipids/blood , Male , Meals , Middle Aged
4.
J Bone Miner Res ; 21(5): 674-83, 2006 May.
Article in English | MEDLINE | ID: mdl-16734382

ABSTRACT

UNLABELLED: Pi handling by osteogenic cells is important for bone mineralization. The role of Pi transport in BMP-2-induced matrix calcification was studied. BMP-2 enhances Pit-1 Pi transporters in osteogenic cells. Experimental analysis suggest that this response is required for bone matrix calcification. INTRODUCTION: Bone morphogenetic proteins (BMPs) are produced by osteogenic cells and play an important role in bone formation. Inorganic phosphate (Pi) is a fundamental constituent of hydroxyapatite, and its transport by osteogenic cells is an important function for primary calcification of the bone matrix. In this study, we investigated the role of Pi transport in BMP-2-induced matrix mineralization. MATERIALS AND METHODS: Confluent MC3T3-E1 osteoblast-like cells were exposed to BMP-2 for various time periods. Pi and alanine transport was determined using radiolabeled substrate, Pit-1 and Pit-2 expression by Northern blot analysis, cell differentiation by alkaline phosphatase activity, matrix mineralization by alizarin red staining, and the characteristics of mineral deposited in the matrix by transmission electron microscopy, electron diffraction analysis, and Fourier transformed infrared resolution (FTIR). RESULTS: BMP-2 time- and dose-dependently stimulated Na-dependent Pi transport in MC3T3-E1 cells by increasing the V(max) of the transport system. This effect was preceded by an increase in mRNA encoding Pit-1 but not Pit-2. BMP-2 also dose-dependently enhanced extracellular matrix mineralization, an effect blunted by either phosphonoformic acid or expression of antisense Pit-1. Enhanced Pi transport and matrix mineralization induced by BMP-2 were blunted by a specific inhibitor of the c-Jun-N-terminal kinase (JNK) pathway. CONCLUSIONS: Results presented in this study indicate that, in addition to its well-known effect on several markers of the differentiation of osteoblastic cells, BMP-2 also stimulates Pi transport activity through a selective increase in expression of type III Pi transporters Pit-1. In MC3T3-E1 cells, this effect is mediated by the JNK pathway and plays an essential role in bone matrix calcification induced by BMP-2.


Subject(s)
Bone Morphogenetic Proteins/physiology , Calcification, Physiologic/physiology , Osteoblasts/metabolism , Transcription Factor Pit-1/physiology , Transforming Growth Factor beta/physiology , 3T3 Cells , Animals , Base Sequence , Bone Morphogenetic Protein 2 , DNA Primers , Mice , Osteoblasts/cytology
5.
Atherosclerosis ; 174(1): 17-24, 2004 May.
Article in English | MEDLINE | ID: mdl-15135246

ABSTRACT

We investigated the effect of platelet-derived growth factor B homodimer (PDGF-BB) on inorganic phosphate (Pi) transport activity, which has been reported to be involved in the mechanism of atherosclerosis, in A-10 rat aortic vascular smooth muscle cells (VSMCs). PDGF-BB time- and dose-dependently stimulated Pi transport in A-10 cells. Using northern blot analysis, the PDGF-BB-enhanced Pi transporter (PiT) in A-10 cells was identified as Pit-1 (Glvr-1), a member of the type III Na-dependent PiT. An inhibitor of PDGF beta-receptor tyrosine kinase suppressed PDGF-BB-induced Pi transport. Both a protein kinase C (PKC) inhibitor calphostin C and PKC down regulation suppressed the stimulatory effect of PDGF-BB on Pi transport. On the other hand, inhibition of mitogen-activated protein (MAP) kinases by selective inhibitors did not affect Pi transport. Ly294002, a phosphatidylinositol (PI) 3-kinase inhibitor, partially attenuated PDGF-BB-induced Pi transport. A selective inhibitor of S(6) kinase, rapamycin, reduced this effect of PDGF-BB, while Akt kinase inhibitor did not. In summary, these results indicated that PDGF-BB is a potent and selective stimulator of Pi transport in VSMCs. The mechanism responsible for this effect is not mediated by MAP kinase, but involves activation of PKC, PI 3-kinase and S(6) kinase.


Subject(s)
Muscle, Smooth, Vascular/cytology , Platelet-Derived Growth Factor/pharmacology , Receptors, Platelet-Derived Growth Factor/metabolism , Analysis of Variance , Animals , Becaplermin , Biological Transport, Active/drug effects , Biological Transport, Active/physiology , Blotting, Northern , Cells, Cultured , Dose-Response Relationship, Drug , Models, Animal , Muscle, Smooth, Vascular/physiology , Probability , Protein Kinase C/metabolism , Proto-Oncogene Proteins c-sis , Rats , Receptors, Platelet-Derived Growth Factor/drug effects , Sodium/metabolism , Sodium/pharmacology
6.
Article in English | MEDLINE | ID: mdl-15062850

ABSTRACT

Prostaglandins are now recognized to be important regulators for both bone formation and resorption. Among them, prostaglandin E(1) (PGE(1)) has been reported to stimulate cAMP accumulation and to induce alkaline phosphatase (ALP) activity, a marker of differentiation, in osteoblast-like cells. Recently, we have shown that p38 mitogen-activated protein (MAP) kinase pathway regulates ALP activity in response to activation of Gi protein-coupled receptors in mouse osteoblast-like MC3T3-E1 cells (Suzuki et al., Endocrinology 140 (1999) 3177). In the present study, we investigated whether p38 MAP kinase is involved in ALP activation by PGE(1) in MC3T3-E1 osteoblast-like cells. PGE(1) dose-dependently enhanced ALP activities in the concentration range between 1 nM and 1 microM in MC3T3-E1 cells. SB203580, a specific inhibitor of p38 MAP kinase, blocked the increase in ALP activity induced by PGE(1). Further analysis with western blotting suggested that PGE(1) induced an increase in tyrosine (Tyr) phosphorylation of p38 MAP kinase. Both Bt(2)cAMP, a permeable analogue of cAMP, and forskolin, which directly activates adenylate cyclase, also induced an increase in Tyr phosphorylation of p38 MAP kinase. H-89, a potent inhibitor of protein kinase A (PKA), significantly suppressed PGE(1)-induced Tyr phosphorylation of p38 MAP kinase. The results of this study suggest that PGE(1) stimulates p38 MAP kinase through the activation of PKA, resulting in the enhancement of ALP activity.


Subject(s)
Alkaline Phosphatase/biosynthesis , Alprostadil/pharmacology , Osteoblasts/enzymology , p38 Mitogen-Activated Protein Kinases/metabolism , Adenylyl Cyclases/metabolism , Animals , Bucladesine/pharmacology , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Line , Colforsin/pharmacology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/metabolism , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Imidazoles/pharmacology , Isoquinolines/pharmacology , Mice , Osteoblasts/cytology , Phosphorylation/drug effects , Pyridines/pharmacology , Sulfonamides/pharmacology , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
7.
Pathol Res Pract ; 207(2): 124-6, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-20943327

ABSTRACT

We report a case of splenic tumor associated with severe hypoglycemia. The patient was a 69-year-old man with a large splenic tumor. He had suffered from relapsing hypoglycemic attacks and the lowest serum glucose level (4 mg/dl). He died 34 months after the onset of symptoms of left abdominal pain. Autopsy revealed large tumors in the spleen, 3 medium sized tumors in the lungs, and several small tumors in the liver. Microscopic studies of the splenic tumors revealed a hepatocellular carcinoma which showed a strongly positive reaction against anti-PIVKA-II and anti-"hepatocyte" antibodies. Several bile ductules thought to be heterotopic remnants of the liver tissues were found in the capsule of the spleen, adjoining the splenic tumor. It was suggested that the tumor originated from one of these ductules. Electron microscopic analysis showed numerous endocrine-like granules of every tumor cell, and 87-165 times stronger mRNA expression of insulin-like growth factor-II was measured in the tumor tissues when compared with normal liver tissue. Owing to these results, we believe that this is the first report of hepatocellular carcinoma that had developed from a liver tissue in the spleen.


Subject(s)
Carcinoma, Hepatocellular/pathology , Choristoma , Insulin-Like Growth Factor II/genetics , Liver Neoplasms/pathology , Liver , Splenic Neoplasms/pathology , Aged , Autopsy , Blood Glucose/metabolism , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/genetics , Fatal Outcome , Humans , Hypoglycemia/blood , Hypoglycemia/etiology , Liver Neoplasms/blood , Liver Neoplasms/complications , Liver Neoplasms/genetics , Male , RNA, Messenger/analysis , Recurrence , Severity of Illness Index , Splenic Neoplasms/blood , Splenic Neoplasms/complications , Splenic Neoplasms/genetics , Tomography, X-Ray Computed , Up-Regulation
8.
Endocr J ; 54(1): 103-12, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17135708

ABSTRACT

We investigated the effect of arginine vasopressin (AVP) on inorganic phosphate (Pi) transport in A-10 rat aortic vascular smooth muscle cells (VSMCs). AVP time- and dose-dependently stimulated Na-dependent Pi transport in A-10 cells. This stimulatory effect of AVP on Pi transport was markedly suppressed by V1 receptor antagonist. A protein kinase C (PKC) inhibitor calphostin C partially suppressed the stimulatory effect of AVP. The selective inhibitors of c-Jun-NH2-terminal mitogen-activated protein (MAP) kinase (Jun kinase) attenuated AVP-induced Pi transport, but Erk kinase or p38 MAP kinase inhibitors did not. Wortmannin, a phosphatidylinositol (PI) 3-kinase inhibitor, suppressed AVP-induced Pi transport. Rapamycin, a selective inhibitor of S6 kinase, reduced this effect of AVP, while Akt kinase inhibitor did not. The combination of inhibitors for PKC, Jun kinase and PI 3-kinase completely suppressed the AVP-enhanced Pi transport. Furthermore, AVP rescued the VSMC from high phosphate-induced cell death and enhanced mineralization of these cells. In summary, these results suggest that AVP stimulates both Na-dependent Pi transport and mineralization in VSMCs. The mechanism is mediated by the activation of multiple signaling pathways including PKC, PI 3-kinase, S6 kinase and Jun kinase.


Subject(s)
Aorta/drug effects , Arginine Vasopressin/pharmacology , Calcinosis/chemically induced , Myocytes, Smooth Muscle/drug effects , Phosphates/metabolism , Sodium-Phosphate Cotransporter Proteins/metabolism , Vascular Diseases/chemically induced , Animals , Aorta/metabolism , Calcium/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Embryo, Mammalian/cytology , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Extracellular Signal-Regulated MAP Kinases/physiology , Myocytes, Smooth Muscle/metabolism , Oncogene Protein v-akt/antagonists & inhibitors , Oncogene Protein v-akt/physiology , Rats , Time Factors
9.
Endocr J ; 50(5): 545-51, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14614210

ABSTRACT

We have developed a new test for estimating the secretory capacity of parathyroid hormone (PTH) from the parathyroid gland. Sodium bicarbonate solution [8.4% (w/v); 35 ml/m(2) body surface area] was infused for 2 min, and blood samples for the determination of plasma ionized calcium, plasma PTH (intact, midregion, carboxy-terminus) and related parameters were serially obtained. In 8 healthy volunteers, the mean (+/-SE) plasma ionized calcium fell promptly and significantly (from 1.21 +/- 0.01 to 1.11 +/- 0.01 mmol/L) after the sodium bicarbonate infusion. The mean (+/-SE) plasma intact PTH increased promptly and significantly, by more than four fold (42.3 +/- 4.2 to 182.4 +/- 34.7 pg/ml), and then gradually returned to basal levels. In patients with partial hypoparathyroidism who have detectable basal plasma levels of PTH, the absolute increment in PTH levels was much less, and in the plasma obtained from patients with complete hypoparathyroidism, absolutely no response was observed. Plasma obtained from patients diagnosed with primary hyperparathyroidism (parathyroid adenoma or hyperplasia) has high basal PTH levels. The response to the sodium bicarbonate infusion in these patients was markedly blunted (less than a two-fold increase in all cases examined). No significant adverse effects were observed during the procedure. Therefore, the sodium bicarbonate infusion test is a simple and sensitive method to stimulate PTH release, and is clinically useful for evaluating parathyroid gland function.


Subject(s)
Hyperparathyroidism/diagnosis , Parathyroid Glands/metabolism , Sodium Bicarbonate/administration & dosage , Adult , Aged , Calcium/blood , Case-Control Studies , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Parathyroid Hormone/blood , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL